

Friday, October 23, 10:30 a.m. – 12:30 p.m. MT

Oral Abstract Session

High-Impact Clinical Trials

Bluebird Ballroom

Moderators: Laura M. Dember, MD, FASN; Meg Jardine, MBBS, PhD

Note: Full abstracts will be posted on the ASN website on the day of presentation, and on the JASN website on November 10.

- 10:30 AM **FR-OR100 ATTACK (Aspirin To Target Arterial events in Chronic Kidney Disease): A Multicentre Randomised Trial of Aspirin vs. Usual Care for the Primary Prevention of Cardiovascular Events in Patients with CKD – Hugh Gallagher, Simon D. Fraser, Sam Wilding, Joshua Northey, Maarten W. Taal, Paul E. Stevens, Robert A. Henderson, Mark Lown, Liz Hartshorne, Jennifer S. Dumbleton, Wendy Daunt, Rosy A. Lampitt, Jonathan N. Townend, Susan Todd, Paul J. Roderick**
- 10:45 AM **FR-OR101 High-Dose Cholecalciferol and Clinical Outcomes in Patients Receiving Dialysis: Results of the SIMPLIFIED Trial – Rona M. Smith, Molly Cui, Fergus Caskey, Afzal Chaudhry, John Cunningham, Toby Humphrey, Sandip Mitra, Inez Schoenmakers, Adam P. Wagner, David C. Wheeler, Ian Wilkinson, Edward C. Wilson, Amer Yahia, Simon Bond, Thomas Hiemstra, on behalf of the SIMPLIFIED Investigators**
- 11:00 AM **FR-OR102 HLX79 (E-602) Plus Rituximab Produces Fast and Durable Responses in Patients with Membranous Nephropathy – Zhilian Li, Xueqing Yu, Qiuling Fan, Li Zuo, Deguang Wang, Rong Lv, Junxia Wang, Zhiming Ye, Hui Xu, Leping S. Shao, Yan Yan, Huijuan Mao, Aimin Zhong, Cheng Chen, Wanhong Lu, Lizhi Cao, Louis Brenner, Li Peng, James W. Broderick, Yunna Zang, Yating Wang, Lin Han, Brad Rovin**
- 11:15 AM **FR-OR103 Post-Authorization Efficacy and Safety (PAES): An Open-Label Post-Authorization Trial of 50 Imlifidase Crossmatch-Positive Deceased-Donor Kidney Transplants in Europe – Oriol Bestard, Amado Andres, Marta Crespo, Fritz Diekmann, Ondrej Viklicky, Dominique Bertrand, Lucrezia Furian, Torbjörn Lundgren, Annelies de Weerd, Rainer Oberbauer, Aiko P. De Vries, Dany Anglicheau, Umberto Maggiore, Fabian Halleck, Miha Arnol, Atul Bagul, Stefan P. Berger, Dirk R. Kuypers, Lutz Renders, Lionel Rostaing, Lina Nilsson, Anna Runström, Jan G. Tollemar, Tomas Lorant**
- 11:30 AM **FR-OR104 Sefaxersen, a Novel mRNA-Targeted Therapy for IgA Nephropathy: Interim Analysis of the Phase 3 IMAGINATION Trial – Jonathan Barratt, Jürgen Floege, Irene L. Noronha, Dana V. Rizk, Hong Zhang, Xiaonong Chen, Dominique Chauveau, Dong Ki Kim, Pedro Augusto M. Souza, Ji (Emmy) Cheng, Vishal Duggal, Nelson Guerreiro, Jeannette Lo, Nadine Schmit, Yixuan Zou, Sean Barbour**
- 11:45 AM **FR-OR105 SWIFT: A Phase 3 Cluster-Randomized Registry Trial of Symptom Monitoring vs. Usual Care in Patients on Hemodialysis – Rachael L. Morton, Chris Brown, Paul N. Bennett, William (Bill) A. Handke, Prerana Nasikkar, Shyamsundar Muthuramalingam, Dana Alhuzaimi, Brendan Smyth, Andrea K. Viecelli, Kathryn Ducharlet, Peter F. Mount, Fergus Caskey, Cécile Couchoud, Stephen P. McDonald, SWIFT Investigators**
- 12:00 PM **FR-OR106 Vadadustat Three Times Weekly for the Treatment of Anemia in Patients Receiving Hemodialysis – Shuchi Anand, Glenn M. Chertow, Myles Wolf, Mary O. Dittrich, Gopa Green, Martha Block, Adrian E. Elorriaga, Stephanie Brillhart, Amanda Leppink, F. David Newby, Carolina Arias, Ayodele Erinle, Irfan Agha, Geoffrey A. Block**
- 12:15 PM **FR-OR107 Effects of Ravulizumab on Proteinuria and Hematuria in Patients with IgAN: A Prespecified Interim Analysis of the Phase 3 I CAN Trial – Richard A. Lafayette, Youssef M. Farag, Kara Rice, Tobin J. Cammett, Lesley Inker, Hernan Trimarchi, Annette Bruchfeld, Hiddo J. Heerspink, Adrian Liew, Kevin Carroll, Hong Zhang, Sayna Norouzi, Shuang Hou, Sehoon Park, Miguel Angel Pérez Valdivia, Jai Radhakrishnan, Yusuke Suzuki, Bonnie Schneider, John Marsala, Cynthia Carrillo Infante, Stephen Lake, Ajay K. Singh, Stephen Nolan, Jonathan Barratt, I CAN Study Group**
- 12:30 p.m. Adjourn

Presenting author indicated by underline.